EUCTR2011-003719-42-LV进行中（未招募）不适用
A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY ANDSAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB+ PLATINUM + PACLITAXEL OR PEMETREXED + PLATINUM ASFIRST-LINE TREATMENT IN PATIENTS WITH STAGE IIIB or IVNON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •Male or female, 18 years of age or older
- •ECOG performance status of 0 or 1
- •Stage IIIB or Stage IV NSCLC tumors of non-squamous histology (Stage IIIB eligible only if stage T4 disease not amenable to definitive surgery or radiation therapy)
- •For patients who received prior adjuvant chemotherapy:
- •a treatment free interval of at least 12 months since the last chemotherapy cycle
- •Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR status is unknown
- •Adequate hematologic, hepatic, and renal function
- •Adequate contraception, during the treatment period and for at least 90 days after the last dose of study drug, if applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 169
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 91
排除标准
- •Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
- •Mixed NSCLC histology with squamous cell predominance
- •Prior exposure to experimental treatment targeting either the HGF or Met pathway
- •Tumors confirmed to have EGFR activating mutations suitable for anti-EGFR therapy
- •Known central nervous system (CNS) disease, other than stable, treated brain metastasis
- •History of another malignancy in the previous 3 years, with a disease-free interval of < 3 years (except for in situ cancer or basal or squamous cell skin cancer)
- •Serum calcium > ULN (corrected for low serum albumin concentrations)
- •Uncontrolled diabetes (fasting serum glucose level > 200 mg/dL)
- •Pregnancy or lactation
- •Significant history of cardiovascular disease
- •Serious active infection or other serious underlying medical conditions
- •Known HIV positivity
- •Any major surgery, major surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1, or an anticipated need for major surgery during the study
- •Known sensitivity to any component of cisplatin or carboplatin
- •(Patients with contraindications to bevacizumab or pemetrexed may not be included in those treatment cohorts)
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy and the safety of MetMAb in combination with paclitaxel+cisplatin or paclitaxel+carboplatin in patients with either locally advanced or metastatic squamous cell lung cancer.MET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 14.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864EUCTR2011-003720-12-GBF. Hoffmann-La Roche Ltd.109
进行中（未招募）
1 期
A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITHPACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, TRIPLE-NEGATIVE BREAST CANCEREstudio aleatorizado, en fase II, multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de metmab en combinación con paclitaxel y bevacizumab en pacientes con cáncer de mama metastásico triple negativoMetastatic, triple-negative breast cancerCáncer de mama metastásico triple negativoMedDRA version: 12.1Level: PTClassification code 10055113Term: Breast cancer metastaticEUCTR2010-020101-32-ESGENENTECH, Inc.120
进行中（未招募）
不适用
A study to evaluate the efficacy and the safety of MetMAb in combination with paclitaxel+cisplatin or paclitaxel+carboplatin in patients with either locally advanced or metastatic squamous cell lung cancer.MET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER(NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2011-003720-12-DEF. Hoffmann-La Roche Ltd.110
进行中（未招募）
不适用
A study to evaluate the efficacy and the safety of MetMAb in combination with paclitaxel+cisplatin or paclitaxel+carboplatin in patients with either locally advanced or metastatic squamous cell lung cancerMET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003720-12-ITF. HOFFMANN - LA ROCHE LTD.110
进行中（未招募）
不适用
A study to evaluate the efficacy and the safety of MetMAb in combination with either bevacizumab + platinum + paclitaxel or pemetrexed + platinum in lung cancer patients (non-squamous non-small cell lung cancer).EUCTR2011-003719-42-ESF. Hoffmann-La Roche Ltd.260